Physician profile
Joseph E Kerschner
NPI 1912958455
$176,138.24
in general payments reported to CMS, 2019-2025
5 companies · $6,925 in 2025
The $6,925 reported for 2025 was more than what 97% of Pediatric Otolaryngology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.43 · 2022: $28K · 2023: $136K · 2024: $5,253 · 2025: $6,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $136K · Consulting Fee: $12K · Food and Beverage: $55.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $135,849.89 |
| Consulting Fee | $12,150.00 |
| Food and Beverage | $55.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $135,849.89 | 2023 | |
| Photonicare INC | $28,071.60 | 2022 | |
| Karl Storz Endovision, INC. | $12,150.00 | 2024-2025 | N.A., Image1 X-Link, Flex-X |
| Bayer Healthcare Pharmaceuticals INC. | $55.32 | 2023-2024 | |
| Cochlear Americas | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$65,959.83 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Kerschner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.